<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Foxp3(+) regulatory T cells (Tregs) play a central role in maintaining immune tolerance </plain></SENT>
<SENT sid="1" pm="."><plain>Their expansion in malignant diseases leads to the suppression of host anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> responses </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we evaluated the clinical significance of Tregs in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: We analysed the number of CD4(+) CD25(+) Foxp3(+) Tregs using three-colour flow cytometry in the peripheral blood of 26 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> classified according to the World Health Organization classification method into four cases of refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> and refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with ringed sideroblasts (RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), 15 cases of refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>), three cases of refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blast-1 (<z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e>) and four cases of refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blast-2 (<z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-2</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>Eighteen healthy volunteers were included as the control group </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The mean absolute numbers of Tregs in the RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> group (0.06 x 10(9)/L; 95% CI, 0.02-0.10 x 10(9)/L) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> group (0.06 x 10(9)/L; 95% CI, 0.02-0.10 x 10(9)/L) were significantly higher than that of the control group (0.03 x 10(9)/L; 95% CI, 0.02-0.03 x 10(9)/L) (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>However, in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> group, there was no significant difference in the mean absolute number of Tregs (0.03 x 10(9)/L; 95% CI, 0.02-0.04 x 10(9)/L) compared with the control group </plain></SENT>
<SENT sid="7" pm="."><plain>Regarding the mean level of the CD8/Foxp3 ratio, there were significant decreases in the RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> group (2.8; 95% CI, 0.7-4.9; P &lt; 0.01), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> group (3.4; 95% CI, 2.0-4.4; P &lt; 0.001) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> group (2.1; 95% CI, 1.7-2.5; P &lt; 0.001) compared with the control group (6.1; 95% CI, 5.1-7.0) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: The expansion of natural CD4(+) Tregs may contribute to the suppression of CD8 through the Th1-mediated immune response in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The low CD8/Foxp3 ratio is a characteristic feature in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>To determine whether the expansion of CD4(+) Tregs contributes to the progression of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes into more aggressive subtypes, more <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases and further follow-up are required </plain></SENT>
</text></document>